Early diagnosis of mild cognitive impairment and Alzheimer's disease based on salivary lactoferrin.

ABSTRACT:

Introduction

The Alzheimer's disease (AD) process is likely initiated many years before clinical onset. Biomarkers of preclinical disease are critical for the development of disease-modifying or even preventative therapies. Current biomarkers for early disease, including cerebrospinal fluid tau and amyloid β (Aβ) levels, structural and functional magnetic resonance imaging, and the use of brain amyloid imaging, are limited because they are very invasive or expensive. Noninvasive biomarkers may be a more accessible alternative, but none can currently detect preclinical AD with the required sensitivity and specificity.

Methods

Here, we show a novel, straight-forward, and noninvasive approach for assessment of early stages of cognitive decline. Salivary samples from cases of am

SUBMITTER: Carro E 

PROVIDER: S-EPMC5470603 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature